Treating functional impairment of autism with selective serotonin-reuptake inhibitors

Annals of Pharmacotherapy

Volumn 38, Issue 9, 2004, Pages 1515-1519

  Moore, Malia L ^a   Eichner, Samantha F ^a,b   Jones, Jennifer R ^b,c  

^a UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^b UNIVERSITY OF TENNESSEE   (United States)

^c Methodist Hlthcare Univ Hospital   (United States)

Author keywords

Autistic disorder; Pervasive developmental disorders; Selective serotonin reuptake inhibitor

Indexed keywords

ANTICONVULSIVE AGENT; ATYPICAL ANTIPSYCHOTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BUSPIRONE; CARBAMAZEPINE; CITALOPRAM; CLOMIPRAMINE; CLONIDINE; DESIPRAMINE; FENFLURAMINE; FLUOXETINE; FLUVOXAMINE; LITHIUM; METHYLPHENIDATE; NALTREXONE; PAROXETINE; PLACEBO; PSYCHOTROPIC AGENT; SEROTONIN; SEROTONIN 2 RECEPTOR; SEROTONIN TRANSPORTER; SEROTONIN UPTAKE INHIBITOR; SERTRALINE;

ABDOMINAL DISCOMFORT; AGGRESSION; AGITATION; AKATHISIA; ALOPECIA; ANOREXIA; ANXIETY DISORDER; APPETITE DISORDER; AUTISM; AUTOMUTILATION; BEHAVIOR DISORDER; CLINICAL FEATURE; CLINICAL TRIAL; DIARRHEA; DISEASE ASSOCIATION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG SCREENING; DRUG TOLERABILITY; DRUG UTILIZATION; EMBASE; EXCITEMENT; FUNCTIONAL DISEASE; HEADACHE; HUMAN; HYPERACTIVITY; INSOMNIA; IRRITABILITY; LETHARGY; MEDICAL LITERATURE; MEDLINE; MENTAL INSTABILITY; NAUSEA; OUTCOMES RESEARCH; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RASH; RATING SCALE; REVIEW; RHINITIS; SEDATION; SIDE EFFECT; SLEEP DISORDER; STEVENS JOHNSON SYNDROME; SYMPTOM; SYNCOPE; SYSTEMATIC REVIEW; TIC; TINNITUS; VIOLENCE; VIVID DREAM; WEIGHT GAIN;

AUTISTIC DISORDER; CITALOPRAM; CLINICAL TRIALS; FLUOXETINE; FLUVOXAMINE; HUMANS; PAROXETINE; RETROSPECTIVE STUDIES; SEROTONIN UPTAKE INHIBITORS; SERTRALINE;

EID: 4143067899     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1D543     Document Type: Review

References (21)

1. Shaffer D, Campbell M, Bradley SJ, Cantwell DP, Carlson GA, Cohen DJ, et al. Disorders usually first diagnosed during infancy, childhood, or adolescence work group. In: First MB, ed. Diagnostic and statistical manual of mental disorders text revision. 4th ed. Washington, DC: American Psychiatric Association, 2000:70-5.
2. Chugani DC. Role of altered brain serotonin mechanisms in autism. Mol Psychiatry 2002;7(suppl 2):516-7.
3. Buitelaar JK, Willemsen-Swinkles SHN. Medication treatment in subjects with autistic spectrum disorders. Eur Child Adolesc Psychiatry 2000; 9(suppl 1):185-97.
4. Cook EH, Leventhal BL. The serotonin system in autism. Curr Opin Pediatr 1996;8:348-54.
5. Tsai LY. Psychopharmacology in autism. Psychosom Med 1999;61:651-65.
6. McDougle CJ, Naylor ST, Cohen DJ, Volkmar FR, Heninger GR, Price LH. A double-blind, placebo-controlled study of fluvoxamine in adults with autistic disorder. Arch Gen Psychiatry 1996;53:1001-8.
7. DeLong GR, Teague LA, McSwain Kamran M. Effects of fluoxetine treatment in young children with idiopathic autism. Dev Med Child Neurol 1998;40:551-62.
8. Cook EH, Rowlett R, Jaselskis C, Leventhal BL. Fluoxetine treatment of children and adults with autistic disorder and mental retardation. J Am Acad Child Adolesc Psychiatry 1992;31:739-45.
9. Peral M, Alcami M, Gilaberte I. Fluoxetine in children with autism. J Am Acad Child Adolesc Psychiatry 1999; 38:1472-3.
10. Hellings JA, Kelley LA, Gabrielli WF, Kilgore E, Shah P. Sertraline response in adults with mental retardation and autistic disorder. J Clin Psychiatry 1996;57:333-6.
11. McDougle CJ, Brodkin ES, Naylor ST, Carlson DC, Cohen DJ, Price LH. Sertraline in adults with pervasive developmental disorders: a prospective open-label investigation. J Clin Psychopharmacol 1998;18:62-6.
12. Martin A, Koenig K, Anderson GM, Scahill L. Low-dose fluvoxamine treatment of children and adolescents with pervasive developmental disorders: a prospective, open-label study. J Autism Dev Disord 2003;33:77-85.
13. Couturier JL, Nicolson R. A retrospective assessment of citalopram in children and adolescents with pervasive developmental disorders. J Child Adolesc Psychopharmacol 2002;12:243-8.
14. Fatemi SH, Realmuto GM, Khan L, Thuras P. Fluoxetine in treatment of adolescent patients with autism: a longitudinal open trial. J Autism Dev Disord 1998;28:303-7.
15. Ghaziuddin M, Tsai L, Ghaziuddin N. Fluoxetine in autism with depression. J Am Acad Child Adolesc Psychiatry 1991;30:508-9.
16. Todd RD. Fluoxetine in autism (letter). Am J Psychiatry 1991;148:1089.
17. Perry DW, Hinder S, Krishnan VHR, Roy A. The use of specific serotonin re-uptake inhibitors in people with learning disability, autism and depression. Hum Psychopharmacol 1996;11:425-6.
18. Steingard RJ, Zimnitzky B, DeMaso DR, Bauman ML, Bucci JP. Sertraline treatment of transition-associated anxiety and agitation in children with autistic disorder. J Child Adolesc Psychopharmacol 1997;7:9-15.
19. Posey DI, Litwiller M, Koburn A. McDougle CJ. Paroxetine in autism. J Am Acad Child Adolesc Psychiatry 1999;38:111-2.
20. Snead RW, Boon F, Presberg J. Paroxetine for self-injurious behavior. J Am Acad Child Adolesc Psychiatry 1994;33:909-10.
21. McDougle CJ, Price LH, Goodman WK. Fluvoxamine treatment of coincident autistic disorder and obsessive-compulsive disorder: a case report. J Autism Dev Disord 1990;20:537-43.